Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Receivables (2016 - 2025)

Ligand Pharmaceuticals' Receivables history spans 16 years, with the latest figure at $59.6 million for Q4 2025.

  • For Q4 2025, Receivables rose 55.31% year-over-year to $59.6 million; the TTM value through Dec 2025 reached $59.6 million, up 55.31%, while the annual FY2025 figure was $59.6 million, 55.31% up from the prior year.
  • Receivables for Q4 2025 was $59.6 million at Ligand Pharmaceuticals, up from $57.6 million in the prior quarter.
  • Across five years, Receivables topped out at $85.5 million in Q4 2021 and bottomed at $28.0 million in Q2 2023.
  • The 5-year median for Receivables is $39.9 million (2025), against an average of $46.2 million.
  • The largest annual shift saw Receivables soared 95.51% in 2021 before it plummeted 64.4% in 2022.
  • A 5-year view of Receivables shows it stood at $85.5 million in 2021, then tumbled by 64.4% to $30.4 million in 2022, then increased by 8.19% to $32.9 million in 2023, then increased by 16.58% to $38.4 million in 2024, then surged by 55.31% to $59.6 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Receivables are $59.6 million (Q4 2025), $57.6 million (Q3 2025), and $41.3 million (Q2 2025).